financetom
Business
financetom
/
Business
/
Bristol Myers' drug fails to meet main goal of late-stage anemia trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bristol Myers' drug fails to meet main goal of late-stage anemia trial
Jul 18, 2025 4:24 AM

July 18 (Reuters) - Bristol Myers Squibb ( BMY ) said on

Friday its drug Reblozyl in combination with another therapy

failed to meet the main goal of a late-stage trial to treat

anemia due to a rare bone marrow cancer.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved